Portola Pharmaceuticals is a spinout of the majority of the COR Therapeutics assets acquired from Millennium Pharmaceuticals and is led by the former COR management team. Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options. The Companys two lead programs address unmet medical needs in the area of thrombosis, or blood clots. The Companys lead compound Betrixaban is an oral once-daily inhibitor of Factor Xa in Phase III development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism (VTE), in acute medically ill patients. The Companys third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic, or blood, cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk), and janus kinases (JAK), enzymes that regulate signaling pathways.
